secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001104659-23-118368
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome presents pipeline update; cash runway into Q1 2026; 177Lu-FAP IND planned 1Q25
--------------------------------------------------------------------------------

- Cash runway expected into Q1 2026; recently completed $125M PIPE with leading healthcare investors.
- Lead programs: first-in-class anti-IL-38 mAb and FAP-targeted radioligand therapy (177Lu-FAP).
- IND filing for 177Lu-FAP anticipated in Q1 2025; preclinical data show single-dose antitumor activity.
- Pipeline includes ADC strategy centered on novel targets; 70 antibody-target pairs identified to date.
- Management team led by former Seagen CEO Clay Siegall; headquarters in Bothell, WA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923118368/0001104659-23-118368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923118368/tm2330767d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-118368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer